| scholarly article | Q13442814 |
| P356 | DOI | 10.4155/FMC.12.217 |
| P698 | PubMed publication ID | 23464522 |
| P2093 | author name string | Chris Twelves | |
| Jenny Seligmann | |||
| P2860 | cites work | Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability | Q24610709 |
| Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale | Q26851529 | ||
| A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients | Q46627004 | ||
| Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. | Q46630298 | ||
| BetaIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability | Q46919957 | ||
| Taxol: mechanisms of action and resistance | Q48421472 | ||
| Biodistribution of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor | Q49135477 | ||
| Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). | Q52196656 | ||
| Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. | Q52548541 | ||
| Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. | Q53144257 | ||
| Mitosis is not a key target of microtubule agents in patient tumors. | Q53271035 | ||
| Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. | Q53442602 | ||
| Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. | Q53599393 | ||
| Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer | Q56626150 | ||
| Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer | Q58614874 | ||
| Halichondrins - antitumor polyether macrolides from a marine sponge | Q62773345 | ||
| Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties | Q71236147 | ||
| Microtubule-binding agents: a dynamic field of cancer therapeutics | Q27690249 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer | Q27851549 | ||
| Trastuzumab emtansine for HER2-positive advanced breast cancer | Q27851917 | ||
| Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma | Q28235707 | ||
| Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment | Q28255226 | ||
| Preclinical discovery of ixabepilone, a highly active antineoplastic agent | Q28272975 | ||
| Abiraterone and increased survival in metastatic prostate cancer | Q29617512 | ||
| Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 | ||
| Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel | Q31152523 | ||
| Pharmacological effects of formulation vehicles : implications for cancer chemotherapy | Q33187648 | ||
| Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT) | Q33361186 | ||
| A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. | Q33375329 | ||
| Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer | Q33389302 | ||
| Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy | Q33393360 | ||
| A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine | Q33401523 | ||
| Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. | Q33561943 | ||
| North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer | Q33618149 | ||
| Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer | Q33852049 | ||
| Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q33990883 | ||
| Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer | Q34203414 | ||
| Structural insight into microtubule function | Q34301115 | ||
| Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. | Q34522032 | ||
| Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial | Q34632818 | ||
| Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate | Q34880994 | ||
| Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanoma | Q35003419 | ||
| Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. | Q35098563 | ||
| A common pharmacophore for cytotoxic natural products that stabilize microtubules | Q35123238 | ||
| Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia | Q35148088 | ||
| Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo | Q35559041 | ||
| Cross-validation study of class III beta-tubulin as a predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of four randomized trials | Q35747285 | ||
| Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer | Q36109584 | ||
| Eribulin mesylate in patients with refractory cancers: a Phase I study | Q36205403 | ||
| Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo | Q36231650 | ||
| Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells | Q36291736 | ||
| Peripheral neuropathy induced by microtubule-stabilizing agents. | Q36436422 | ||
| Exploiting the enhanced permeability and retention effect for tumor targeting | Q36578875 | ||
| Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer | Q36667452 | ||
| Tumour targeting by microtubule-depolymerizing vascular disrupting agents | Q37008845 | ||
| Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? | Q37073084 | ||
| Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy | Q37125330 | ||
| Novel C-seco-taxoids possessing high potency against paclitaxel-resistant cancer cell lines overexpressing class III beta-tubulin | Q37238550 | ||
| Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies | Q37367110 | ||
| Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes | Q37372150 | ||
| Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer | Q37496425 | ||
| From signaling pathways to microtubule dynamics: the key players. | Q37661807 | ||
| Microtubules and resistance to tubulin-binding agents | Q37690565 | ||
| Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine | Q37777290 | ||
| Chemotherapy-induced peripheral neuropathy: prevention and treatment | Q37911252 | ||
| A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer | Q37944440 | ||
| Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins | Q38305006 | ||
| Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. | Q39582682 | ||
| Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer | Q39855292 | ||
| Non-anti-mitotic concentrations of taxol reduce breast cancer cell invasiveness | Q39901043 | ||
| Preclinical efficacy spectrum and pharmacokinetics of ixabepilone | Q40000960 | ||
| In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases | Q40241012 | ||
| Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. | Q40322378 | ||
| Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells | Q40344963 | ||
| Macrocyclic ketone analogues of halichondrin B. | Q40504671 | ||
| Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer | Q42653377 | ||
| Paclitaxel induces axonal microtubules polar reconfiguration and impaired organelle transport: implications for the pathogenesis of paclitaxel-induced polyneuropathy | Q43281593 | ||
| Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilization of yeast microtubules | Q43921221 | ||
| Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial | Q44102232 | ||
| Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. | Q44280070 | ||
| The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography | Q45009271 | ||
| Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. | Q45976200 | ||
| Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel. | Q45994576 | ||
| Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q46059531 | ||
| Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. | Q46068571 | ||
| Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. | Q46119122 | ||
| Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors | Q46160687 | ||
| Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-hodgkin's lymphoma | Q46197928 | ||
| Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial | Q46454181 | ||
| Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer | Q46466799 | ||
| Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer | Q46507139 | ||
| Morphological and morphometric analysis of paclitaxel and docetaxel-induced peripheral neuropathy in rats | Q46507706 | ||
| Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer | Q46516617 | ||
| P433 | issue | 3 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 339-352 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Future Medicinal Chemistry | Q19280078 |
| P1476 | title | Tubulin: an example of targeted chemotherapy | |
| P478 | volume | 5 |
| Q38755322 | 2-Anilino-3-Aroylquinolines as Potent Tubulin Polymerization Inhibitors |
| Q61453755 | Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action |
| Q58547427 | Antiproliferative Activity and Molecular Docking of Novel Double-Modified Colchicine Derivatives |
| Q35185097 | CCR 20th anniversary commentary: BMS-247550—microtubule stabilization as successful targeted therapy |
| Q38963815 | Design and synthesis of aminostilbene-arylpropenones as tubulin polymerization inhibitors |
| Q58705926 | Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3',4',5'-trimethoxyphenyl)-3-(2'-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach |
| Q46207470 | Differential involvement of glutathione S-transferase mu 1 and multidrug resistance protein 1 in melanoma acquired resistance to vinca alkaloids. |
| Q93087101 | Eribulin rapidly inhibits TGF-β-induced Snail expression and can induce Slug expression in a Smad4-dependent manner |
| Q36996281 | Ferrocenyl 2,5-Piperazinediones as Tubulin-Binding Organometallic ABCB1 and ABCG2 Inhibitors Active against MDR Cells |
| Q38952778 | Microtubule destabilising agents: far more than just antimitotic anticancer drugs |
| Q38434222 | New Colchicine-Derived Triazoles and Their Influence on Cytotoxicity and Microtubule Morphology. |
| Q27011766 | Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis |
| Q49787954 | Regulation of E-cadherin localization by microtubule targeting agents: rapid promotion of cortical E-cadherin through p130Cas/Src inhibition by eribulin |
| Q90163186 | Synthesis and Antiproliferative Screening Of Novel Analogs of Regioselectively Demethylated Colchicine and Thiocolchicine |
| Q59794796 | Synthesis and Biological Evaluation of Novel Triple-Modified Colchicine Derivatives as Potent Tubulin-Targeting Anticancer Agents |
| Q40095321 | The size of the EB cap determines instantaneous microtubule stability |
Search more.